BIOCON.NS Biocon Limited Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
20:41
Feb 03
Feb 03
Biocon among generic semaglutide launch winners
Author includes Biocon among generic semaglutide makers that will launch in Canada, Brazil, and India, and says he has held and likes all these generic companies more than NVO. The thesis is that semaglutide patent expirations create a generic opportunity in large markets. Main stated risk is not specific to Biocon, though the space is competitive and the author says Teva has already ripped 70%.
MED
03:38
Feb 02
Feb 02
Biopharma SHAKTI budget scheme supports leading biosimilars player.
The author sees Biocon as one of the biggest pharma/biotech winners from the budget due to the new Biopharma SHAKTI scheme with Rs 10,000 crore outlay. The scheme aims to make India a global hub for biologics and biosimilars through domestic manufacturing, R&D, and clinical trials. Since Biocon is already India's leading player in biosimilars and complex biologics, this direct policy support should help it scale faster and capture more market share.
HIGH
About BIOCON.NS Investor Commentary
Across the available history and selected sources, Buzzberg tracks BIOCON.NS (Biocon Limited) across 2 sources: 2 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: u/TheAirNearMyFingers, u/JoTumMereHo.